Sera Prognostics (SERA) Set to Release Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) is projected to release its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Sera Prognostics to post earnings of ($0.14) per share and revenue of $0.07 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.03). Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 47,475.72%. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.07 million. On average, analysts expect Sera Prognostics to post ($0.62) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

Sera Prognostics Price Performance

SERA stock traded up $0.01 on Monday, hitting $2.07. 303 shares of the company were exchanged, compared to its average volume of 44,114. Sera Prognostics has a twelve month low of $1.56 and a twelve month high of $3.85. The business’s fifty day moving average is $2.05 and its two-hundred day moving average is $2.15. The stock has a market capitalization of $81.58 million, a price-to-earnings ratio of -3.08 and a beta of 1.14.

Insider Buying and Selling at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 20,139 shares of Sera Prognostics stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $2.00, for a total value of $40,278.00. Following the transaction, the chief executive officer owned 844,870 shares of the company’s stock, valued at $1,689,740. The trade was a 2.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 39,661 shares of company stock worth $79,563. Company insiders own 11.30% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings raised Sera Prognostics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a women’s health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company uses proteomics, bioinformatics and clinical data to develop diagnostic and prognostic products designed to identify risks associated with pregnancy complications.

Its lead product is the PreTRM test, a blood-based test intended to assess a pregnant woman’s risk of spontaneous preterm birth in a singleton pregnancy. The test measures specific protein biomarkers and is designed to provide physicians with information that may support risk assessment, patient management and care planning during pregnancy.

Founded in 2008 and headquartered in Salt Lake City, Utah, Sera Prognostics primarily serves the U.S.